Cholinesterase, Plasma
Test Summary
Approximately 1 in every 2500 individuals has inherited defective or deficiency of the enzyme (pseudocholinesterase) that metabolizes succinylcholine (an anesthetic agent). With "normal" dosage, these individuals have prolonged apnea. Such individuals are responsive at much smaller concentrations of this anesthetic agent than the general population. Low concentrations of pseudocholinesterase are observed in individuals exposed to organophosphorous insecticides and patients with hepatic dysfunction.
Aliases
- N/A
Specimen Collection
Special Instructions
N/A
Preferred Specimen
1 mL plasma collected in an EDTA (lavender-top) tube
Minimum Volume
0.5 mL
Instructions
Draw a lavender-top (EDTA) tube of whole blood. Spin tube to separate plasma. Pour plasma into plastic aliquot tube and refrigerate until shipping. Ship plasma sample refrigerated. Do not send packed cells. Do not send one tube of whole blood.
Plasma cholinesterase results are not accurate if plasma sample is not separated from RBC's in a timely manner (within 1 hour). Hemolyzed plasma samples are not acceptable. Hemolysis can lead to apparent increases in plasma cholinesterase activity, and could mask an enzyme deficiency.
Plasma cholinesterase results are not accurate if plasma sample is not separated from RBC's in a timely manner (within 1 hour). Hemolyzed plasma samples are not acceptable. Hemolysis can lead to apparent increases in plasma cholinesterase activity, and could mask an enzyme deficiency.
Patient Preparation
N/A
Storage
Plastic screw-cap vial
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
- Room temperature: 21 days
- Refrigerated: 21 days
- Frozen: 30 days
Limitations
Results may be depressed in patients who consume oral contraceptives. Hepatic disease may cause up to a 70% decrease in enzyme levels. Cholinesterase may be slightly elevated in patients with obesity or diabetes.
Other Acceptable Specimens
none
Unacceptable Specimens
Hemolysis
Order Code
CHOLPL
EPIC (Premier) Code
LAB105
Includes
N/A
CPT Code
- 82480
Billing Code
- 670386
CPT Statement
Methodology
Kinetic Spectrophotometry (KS)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Physician Attestation of Informed Consent
N/A
Testing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly VA, 20153
14225 Newbrook Drive
Chantilly VA, 20153
Department
Reference Testing
Reference Range
| Male | 3334-7031 IU/L | |
| Female | 2504-6297 IU/L | |
Setup Schedule / Expected Turnaround Time
Monday - Friday; Report available: Next day
Specimen Collection
Special Instructions
N/A
Preferred Specimen
1 mL plasma collected in an EDTA (lavender-top) tube
Minimum Volume
0.5 mL
Instructions
Draw a lavender-top (EDTA) tube of whole blood. Spin tube to separate plasma. Pour plasma into plastic aliquot tube and refrigerate until shipping. Ship plasma sample refrigerated. Do not send packed cells. Do not send one tube of whole blood.
Plasma cholinesterase results are not accurate if plasma sample is not separated from RBC's in a timely manner (within 1 hour). Hemolyzed plasma samples are not acceptable. Hemolysis can lead to apparent increases in plasma cholinesterase activity, and could mask an enzyme deficiency.
Plasma cholinesterase results are not accurate if plasma sample is not separated from RBC's in a timely manner (within 1 hour). Hemolyzed plasma samples are not acceptable. Hemolysis can lead to apparent increases in plasma cholinesterase activity, and could mask an enzyme deficiency.
Patient Preparation
N/A
Storage
Plastic screw-cap vial
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
- Room temperature: 21 days
- Refrigerated: 21 days
- Frozen: 30 days
Limitations
Results may be depressed in patients who consume oral contraceptives. Hepatic disease may cause up to a 70% decrease in enzyme levels. Cholinesterase may be slightly elevated in patients with obesity or diabetes.
Other Acceptable Specimens
none
Unacceptable Specimens
Hemolysis
Result Information
Methodology
Kinetic Spectrophotometry (KS)
Testing Laboratory
N/A
Reference Range
| Male | 3334-7031 IU/L | |
| Female | 2504-6297 IU/L | |
Setup Schedule / Expected Turnaround Time
Monday - Friday; Report available: Next day